查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018849

尿道結石治療器械市場：全球市場預測（按器械類型、治療方法、器械材料、應用和最終用戶分類），2026年至2032年

Urolithiasis Management Devices Market by Device Type, Treatment Type, Device Material, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，用於治療尿道結石的設備的市場規模將達到 5.2703 億美元，到 2026 年將成長到 5.691 億美元，到 2032 年將達到 9.037 億美元，複合年成長率為 8.00%。

主要市場統計數據
基準年 2025 5.2703億美元
預計年份：2026年 5.691億美元
預測年份 2032 9.037億美元
複合年成長率 (%) 8.00%

全面概述當前臨床實踐、技術創新以及影響尿道結石結石治療設備研發和推廣的相關人員壓力。

用於治療尿道結石的器械正處於工程創新、不斷發展的臨床方案和不斷變化的醫療服務模式的交匯點。過去十年，影像學、內視鏡視覺化技術的進步以及體內能量傳遞的逐步改進，共同拓展了治療選擇，並最佳化了患者照護流程。本文概述了當前泌尿系統結石治療領域的現狀，重點闡述了器械設計、材料科學和手術人體工學如何不斷改進，以最佳化結石清除和患者康復，同時最大限度地減少創傷。

圖表展示了由小型化設備、一次性技術和整合數位平台帶來的變革性變化：這些正在重塑行動和實施的流程。

尿道結石的治療現狀正經歷著變革，這主要得益於器械小型化、能量輸送方式的進步以及數位化診斷技術的融合。小型化的輸尿管鏡和軟式內視鏡擴大了內視鏡可治療的結石範圍，減少了對侵入性手術的依賴。同時，體內碎石術的進步，特別是雷射平台在碎石效率和熱安全性之間的平衡性提升，正在改變治療方案，並增加可在門診完成的病例數量。

分析 2025 年關稅制度的變化和貿易結構調整將如何影響整個醫療設備供應鏈的籌資策略、成本結構和採購韌性。

2025年的關稅政策變化和國際貿易趨勢為製造商、供應商和醫療器材買家帶來了新的營運考量。某些醫療設備組件關稅的提高，以及地緣政治發展引發的供應鏈重組，迫使相關人員重新評估籌資策略和成本結構。重要的是，這些貿易措施凸顯了建立能夠應對跨境成本和前置作業時間波動的彈性採購結構的必要性。

將醫療設備類型、治療方法、材料、臨床應用和最終用戶需求與策略性產品定位連結起來的詳細細分見解。

有效的市場區隔分析揭示了臨床需求、技術適用性和購買行為之間的交集。基於醫療設備類型，市場研究涵蓋導管導引線、碎石器、支架和輸尿管鏡等領域，每種器材都展現出其獨特的發展軌跡。導管導引線專注於尖端控制和塗層技術；碎石器追求高效碎石並最大限度減少對周圍組織的影響；支架透過材料科學最佳化患者舒適度和抗粘連性；輸尿管鏡則在光學性能、柔軟性和耐用性之間尋求平衡。依治療方法，市場分析涵蓋體外震波碎石術、體內碎石術和經皮腎鏡取石術，每種治療方法對能量輸送、入路器械和影像整合等方面都有其獨特的器械需求。

關鍵區域考慮因素概述了主要區域在法規、報銷和臨床實踐環境方面的差異如何影響醫療設備的引進和商業化。

區域趨勢影響臨床實務模式、監管路徑和報銷環境，進而影響醫療設備的設計和市場進入策略。在美洲，微創技術在醫療保健系統中廣泛應用，且營運效率和以患者為中心的療效證據備受重視，因此供應商不僅需要提供臨床數據，還需要提供衛生經濟學的論述。該地區的採購週期通常受到整合醫療網路和聯合採購組織的影響，這進一步凸顯了擴充性的供應模式和服務支援的重要性。

深入洞察老牌巨頭和敏捷創新者如何透過產品設計、服務模式和策略夥伴關係實現差異化競爭考察。

競爭格局由成熟的醫療設備製造商、創新醫療技術Start-Ups和專業零件供應商組成，各方都採取差異化策略，力求贏得臨床機構的青睞和採購部門的關注。領先的產品開發團隊致力於將設計能力與臨床醫生的工作流程相匹配，強調人體工學、直覺的操作以及與影像系統的互通性。隨著醫院和手術中心尋求能夠提供培訓、維護和數據分析以最佳化設備使用的合作夥伴，合約和售後支援能力正日益成為供應商之間重要的差異化因素。

透過協調產品設計、製造靈活性、供應鏈韌性和證據生成，加速臨床部署和商業性成功的實用建議。

產業領導企業應採取多管齊下的方法，使研發重點與實際臨床工作流程和採購需求保持一致。首先，優先考慮人性化的設計，以縮短手術時間，提高使用者的人體工學舒適度，並確保新型醫療設備與現有成像和導航系統無縫整合。其次，投資於模組化和擴充性的生產策略，以實現可重複使用和一次性生產路線之間的快速轉換，從而解決感染控制問題並滿足採購偏好。

採用透明的混合方法調查方法，結合對臨床醫師的訪談、技術文獻回顧和情境分析，來檢驗趨勢和影響。

本研究採用混合方法，將一手質性研究與二手公共資訊來源和技術文獻結合。一手資訊來源包括對關鍵專科臨床醫生、不同醫療機構的採購經理以及行業高管進行的結構化訪談，旨在檢驗技術趨勢並識別營運挑戰。二手資料包括同行評審的臨床研究、監管申報文件、醫療設備技術規範以及專業協會發布的公開指南，以確保技術準確性和語境一致性。

摘要重點闡述了臨床創新、營運實際情況和策略需求之間的融合，這些融合將決定尿道結石治療裝置未來發展的走向。

尿道結石的治療正處於一個轉折點，醫療設備的迭代創新、手術流程的演變以及供應鏈的複雜性正在重塑臨床路徑。內視鏡柔軟性、能量傳輸和一次性技術的進步正在拓展微創治療的選擇範圍，並加速向門診治療的轉變。同時，貿易趨勢和區域差異要求制定更精細的籌資策略和更貼近本地市場的商業化方案。因此，決策者必須權衡技術進步的潛力與供應鏈韌性和實證價值等實際因素。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：尿道結石治療器械市場：依器械類型分類

  • 導管導引線
  • 破碎機
  • 支架
  • 輸尿管鏡

第9章：尿道結石（依治療方法分類）

  • 體外震波碎石術
  • 體內取石術
  • 經皮腎鏡取石術

第10章：尿道結石治療器械市場－依器械材料分類

  • 金屬基元件
  • 聚合物元件

第11章：尿道結石治療器材市場：依應用領域分類

  • 膀胱結石
  • 腎結石
  • 輸尿管結石

第12章：尿道結石治療設備市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所

第13章：尿道結石治療器材市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：尿道結石治療器械市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：尿道結石治療器械市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國尿道結石治療器械市場

第17章：中國尿道結石治療器械市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Advanced MedTech Holdings
  • AKSM, Ltd.
  • Avvio Medical, Inc.
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Calyxo Inc.
  • Coloplast A/S
  • Cook Group Incorporated
  • DirexGroup
  • Dornier MedTech GmbH
  • Dyne Medical Group Inc.
  • EMS Electro Medical Systems SA
  • EDAP TMS SA
  • Elmed Lithotripsy Systems
  • EndoTheia, Inc.
  • Karl Storz GmbH & Co. KG
  • Nissha Medical Technologies
  • Olympus Corporation
  • Quanta System SpA
  • Richard Wolf GmbH
  • Siemens Healthineers
  • SonoMotion
  • Teleflex Incorporated
Product Code: MRR-ED54C46E9009

The Urolithiasis Management Devices Market was valued at USD 527.03 million in 2025 and is projected to grow to USD 569.10 million in 2026, with a CAGR of 8.00%, reaching USD 903.70 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 527.03 million
Estimated Year [2026] USD 569.10 million
Forecast Year [2032] USD 903.70 million
CAGR (%) 8.00%

A comprehensive introduction that frames current clinical practices, technological innovation, and stakeholder pressures shaping urolithiasis device development and adoption

Urolithiasis management devices occupy a dynamic intersection of engineering innovation, evolving clinical protocols, and shifting care delivery models. Over the past decade, incremental improvements in imaging, endoscopic visualization, and intracorporeal energy delivery have converged to expand treatment options and refine patient pathways. This introduction synthesizes the current landscape by highlighting how device design, material science, and procedural ergonomics are increasingly tailored to minimize invasiveness while optimizing stone clearance and patient recovery.

Clinicians now prioritize devices that offer reproducible outcomes with predictable safety profiles, and manufacturers respond by focusing on modularity, single-use options, and integration with digital platforms for procedural guidance. Payers and health systems demand demonstrable improvements in throughput and post-procedure resource utilization, which in turn shapes procurement preferences. In sum, the sector is characterized by rapid technical iteration, growing emphasis on user experience, and a continuous recalibration of value propositions to meet clinical and economic performance requirements.

Illustration of transformative shifts driven by device miniaturization, disposable technologies, and integrated digital platforms reshaping procedural pathways and adoption

The landscape of urolithiasis management is undergoing transformative shifts driven by advances in device miniaturization, energy delivery modalities, and integration of digital diagnostics. Miniaturized ureteroscopes and flexible endoscopes are widening the spectrum of stones that can be managed endoscopically, reducing reliance on more invasive procedures. Concurrently, enhancements in intracorporeal lithotripsy-particularly the refinement of laser platforms that balance fragmentation efficiency with thermal safety-have altered procedural algorithms, increasing case volumes that can be completed in ambulatory settings.

Beyond pure device performance, there is a pronounced movement toward disposability and single-use technologies to address infection control concerns and streamline sterilization workflows. The rise of data-enabled devices that provide procedural analytics and imaging enhancement tools is creating opportunities for outcome tracking and operator training. Moreover, regulatory expectations and reimbursement frameworks are evolving in tandem, encouraging manufacturers to demonstrate not only clinical efficacy but also measurable operational benefits, which reshapes product positioning and commercialization strategies.

Analysis of how evolving tariff regimes and trade realignments in 2025 are influencing sourcing strategies, cost structures, and procurement resilience across the device supply chain

Tariff policy changes and international trade dynamics in 2025 have introduced new operational considerations for manufacturers, suppliers, and healthcare purchasers. Increased duties on specific medical device components, coupled with supply chain realignments catalyzed by geopolitical developments, have compelled stakeholders to reassess sourcing strategies and cost structures. Importantly, these trade measures have emphasized the need for resilient procurement frameworks that account for variable cross-border costs and lead times.

In response, many organizations are diversifying supplier bases and evaluating nearshoring opportunities to mitigate exposure to import-related volatility. Device designers are also reconsidering bill-of-materials choices, favoring materials and subcomponents that are locally available or subject to lower trade barriers. For clinical providers, procurement teams are increasingly incorporating total-cost-of-ownership analyses that account for tariff impacts, logistics, and inventory buffers, thereby influencing purchasing cycles and contractual arrangements with manufacturers and distributors.

Deep segmentation insights that connect device types, treatment modalities, materials, clinical applications, and end-user requirements to strategic product positioning

Effective segmentation analysis illuminates where clinical need, technology fit, and purchasing behavior intersect. Based on Device Type, the landscape is studied across Guidewires, Lithotripters, Stents, and Ureteroscopes, revealing distinct development trajectories: guidewires emphasize tip control and coating technology, lithotripters pursue energy-efficient fragmentation with minimal collateral tissue effect, stents optimize patient comfort and encrustation resistance through material science, and ureteroscopes balance optics with flexibility and durability. Based on Treatment Type, the market is studied across Extracorporeal Shock Wave Lithotripsy, Intracorporeal Lithotripsy, and Percutaneous Nephrolithotomy, and each modality drives unique device requirements related to energy delivery, access instrumentation, and imaging integration.

Based on Device Material, the market is studied across Metal-Based Devices and Polymer-Based Devices, which underlines trade-offs between strength, flexibility, cost, and biocompatibility that influence clinical selection and lifecycle management. Based on Application, the market is studied across Bladder Stones, Kidney Stones, and Ureteral Stones, highlighting how stone location dictates access strategy, instrument size, and post-procedural follow-up. Finally, based on End User, the market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics, with each setting prioritizing different value drivers such as throughput, device turnaround time, or procedural complexity. Taken together, these segmentation lenses provide a multi-dimensional view that informs product development priorities and commercialization tactics.

Key regional considerations outlining how divergent regulatory, reimbursement, and clinical practice environments across major geographies shape device adoption and commercialization

Regional dynamics influence clinical practice patterns, regulatory pathways, and reimbursement landscapes, which in turn shape device design and go-to-market strategies. In the Americas, health systems exhibit a high adoption rate of minimally invasive techniques and place strong emphasis on evidence demonstrating operational efficiency and patient-centered outcomes, prompting vendors to support health economic narratives alongside clinical data. Procurement cycles in this region are often influenced by integrated delivery networks and group purchasing organizations, which amplifies the importance of scalable supply models and service support.

In Europe, Middle East & Africa, heterogeneity in regulatory expectations and payer structures requires adaptable market entry strategies that balance localized clinical validation with flexible commercial models. Stakeholders in this region may prioritize cost-effectiveness and durability, especially in systems with constrained capital allocation. Within the Asia-Pacific region, rapid infrastructure development and high procedure volumes create significant demand for cost-effective, scalable devices and single-use solutions that address infection control and throughput. Across all regions, partnerships with local distributors and targeted clinician engagement remain central to adoption and long-term market development.

Critical competitive insights into how established players and agile innovators are differentiating through product design, service models, and strategic partnerships

The competitive landscape comprises established device manufacturers, innovative medtech startups, and specialized component suppliers, each pursuing differentiated strategies to capture clinical preference and procurement attention. Leading product development teams focus on aligning design features with clinician workflows, emphasizing ergonomics, intuitive controls, and interoperability with imaging systems. Contracting and post-market support capabilities increasingly differentiate suppliers, as hospitals and surgical centers seek partners that provide training, maintenance, and data analytics to optimize utilization.

Concurrently, some companies are adopting focused plays-such as single-use platforms or high-powered laser systems-while others concentrate on incremental improvements to guidewires and stents through advanced materials. Strategic alliances, licensing arrangements, and targeted acquisitions are common tactics used to accelerate capability expansion, particularly in areas like imaging integration and disposable instrument portfolios. Ultimately, companies that combine clinical credibility, supply resilience, and compelling value demonstrations are positioned to lead in a landscape that prizes both innovation and operational performance.

Actionable recommendations that align product design, manufacturing agility, supply chain resilience, and evidence generation to accelerate clinical adoption and commercial success

Industry leaders should adopt a multi-pronged approach that aligns R&D priorities with real-world clinical workflows and procurement demands. First, prioritize human-centered design to reduce procedure time and improve user ergonomics, ensuring that new devices integrate seamlessly with existing imaging and navigation systems. Second, invest in modular and scalable manufacturing strategies that allow rapid shifts between reusable and single-use production pathways, thereby responding to infection control concerns and procurement preferences.

Third, strengthen supply chain resilience by diversifying suppliers, evaluating nearshoring opportunities, and embedding tariff and logistics scenarios into commercial planning. Fourth, cultivate robust clinical evidence and health economic dossiers that speak directly to institutional decision-makers, demonstrating not only clinical outcomes but also downstream operational benefits. Lastly, pursue targeted partnerships with regional distributors and training centers to accelerate adoption, while offering post-sale analytics and education services that support sustained utilization and long-term customer relationships.

A transparent mixed-methods research methodology integrating clinician interviews, technical literature review, and scenario analysis to validate trends and implications

This research synthesis is built on a mixed-methods approach that triangulates primary qualitative engagement with secondary public domain sources and technical literature. Primary inputs included structured interviews with clinicians across key specialties, procurement leads from diverse care settings, and industry executives to validate technology trends and identify operational pain points. Secondary research encompassed peer-reviewed clinical studies, regulatory filings, device technical specifications, and publicly available guidance from professional societies to ensure technical accuracy and context.

Analytical methods combined thematic coding of qualitative interviews with cross-sectional comparison of device features and clinical application requirements. Where applicable, supply chain and policy impacts were assessed through scenario analysis to understand sensitivity to trade and logistics variables. Throughout, findings were corroborated across multiple sources to strengthen validity and presented with transparency about data provenance and methodological limits so that decision-makers can interpret insights with appropriate confidence.

Concluding synthesis highlighting the convergence of clinical innovation, operational realities, and strategic imperatives that will define future progress in urolithiasis device management

The management of urolithiasis is at an inflection point where iterative device innovation, procedural evolution, and supply chain complexities converge to redefine clinical pathways. Advances in scope flexibility, energy delivery, and single-use technologies are expanding minimally invasive options and supporting shifts toward ambulatory care. Meanwhile, trade dynamics and regional heterogeneity necessitate more sophisticated procurement strategies and localized commercialization approaches. Decision-makers must therefore balance the promise of technological improvements with pragmatic considerations around supply resilience and evidence-backed value.

Moving forward, stakeholders who successfully align product development with clinician workflows, invest in demonstrable outcome metrics, and build flexible manufacturing and distribution models will capture the greatest opportunity to influence care delivery. The convergence of clinical needs, regulatory expectations, and operational priorities creates fertile ground for innovations that are not only clinically superior but also operationally compelling, ultimately improving patient outcomes and health system efficiency.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Urolithiasis Management Devices Market, by Device Type

  • 8.1. Guidewires
  • 8.2. Lithotripters
  • 8.3. Stents
  • 8.4. Ureteroscopes

9. Urolithiasis Management Devices Market, by Treatment Type

  • 9.1. Extracorporeal Shock Wave Lithotripsy
  • 9.2. Intracorporeal Lithotripsy
  • 9.3. Percutaneous Nephrolithotomy

10. Urolithiasis Management Devices Market, by Device Material

  • 10.1. Metal-Based Devices
  • 10.2. Polymer-Based Devices

11. Urolithiasis Management Devices Market, by Application

  • 11.1. Bladder Stones
  • 11.2. Kidney Stones
  • 11.3. Ureteral Stones

12. Urolithiasis Management Devices Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Urolithiasis Management Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Urolithiasis Management Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Urolithiasis Management Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Urolithiasis Management Devices Market

17. China Urolithiasis Management Devices Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Advanced MedTech Holdings
  • 18.6. AKSM, Ltd.
  • 18.7. Avvio Medical, Inc.
  • 18.8. Becton, Dickinson and Company
  • 18.9. Boston Scientific Corporation
  • 18.10. Calyxo Inc.
  • 18.11. Coloplast A/S
  • 18.12. Cook Group Incorporated
  • 18.13. DirexGroup
  • 18.14. Dornier MedTech GmbH
  • 18.15. Dyne Medical Group Inc.
  • 18.16. E.M.S. Electro Medical Systems S.A.
  • 18.17. EDAP TMS SA
  • 18.18. Elmed Lithotripsy Systems
  • 18.19. EndoTheia, Inc.
  • 18.20. Karl Storz GmbH & Co. KG
  • 18.21. Nissha Medical Technologies
  • 18.22. Olympus Corporation
  • 18.23. Quanta System S.p.A.
  • 18.24. Richard Wolf GmbH
  • 18.25. Siemens Healthineers
  • 18.26. SonoMotion
  • 18.27. Teleflex Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY GUIDEWIRES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY GUIDEWIRES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY GUIDEWIRES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY LITHOTRIPTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY LITHOTRIPTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY LITHOTRIPTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY URETEROSCOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY URETEROSCOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY URETEROSCOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY INTRACORPOREAL LITHOTRIPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY INTRACORPOREAL LITHOTRIPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY INTRACORPOREAL LITHOTRIPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY PERCUTANEOUS NEPHROLITHOTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY PERCUTANEOUS NEPHROLITHOTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY PERCUTANEOUS NEPHROLITHOTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY METAL-BASED DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY METAL-BASED DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY METAL-BASED DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY POLYMER-BASED DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY POLYMER-BASED DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY POLYMER-BASED DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY BLADDER STONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY BLADDER STONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY BLADDER STONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY KIDNEY STONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY KIDNEY STONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY KIDNEY STONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY URETERAL STONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY URETERAL STONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY URETERAL STONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. GCC UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GCC UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. GCC UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. GCC UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 112. GCC UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. GCC UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. G7 UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. G7 UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. G7 UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. G7 UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 130. G7 UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. G7 UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. NATO UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. NATO UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. NATO UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. NATO UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 136. NATO UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. NATO UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)